Kukje Pharma Co., Ltd. (KRX:002720)
South Korea · Delayed Price · Currency is KRW 3,435.00
+50.00 (1.48%)
Sep 1, 2026, 3:30 PM KST
Kukje Pharma Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 68,927 | 87,559 | 103,034 | 119,890 | 106,115 | 112,861 | |
Market Cap Growth | -27.98% | -15.02% | -14.06% | 12.98% | -5.98% | -36.19% |
Enterprise Value | 84,599 | 99,924 | 124,008 | 140,751 | 127,215 | 143,804 |
Last Close Price | 3385.00 | 4273.70 | 4997.94 | 5847.40 | 5173.86 | 5500.86 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 14.09 | 15.37 | 19.80 | - | 29.83 | - |
PS Ratio | 0.38 | 0.50 | 0.66 | 0.89 | 0.84 | 0.94 |
PB Ratio | 0.69 | 0.90 | 1.15 | 1.41 | 1.43 | 1.65 |
P/TBV Ratio | 0.70 | 0.91 | 1.16 | 1.43 | 1.45 | 1.67 |
P/FCF Ratio | 29.65 | 39.51 | 100.14 | 47.40 | 20.23 | 14.65 |
P/OCF Ratio | 10.30 | 15.01 | 26.15 | 33.53 | 16.32 | 11.76 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 0.47 | 0.57 | 0.79 | 1.04 | 1.00 | 1.20 |
EV/EBITDA Ratio | 11.07 | 10.62 | 12.52 | 63.55 | 13.03 | 52.42 |
EV/EBIT Ratio | 19.79 | 16.16 | 18.50 | - | 24.13 | - |
EV/FCF Ratio | 36.39 | 45.09 | 120.53 | 55.65 | 24.26 | 18.66 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.32 | 0.31 | 0.33 | 0.36 | 0.39 | 0.53 |
Debt / EBITDA Ratio | 4.00 | 3.23 | 2.98 | 13.84 | 2.93 | 13.12 |
Debt / FCF Ratio | 13.50 | 13.72 | 28.68 | 12.12 | 5.45 | 4.67 |
Net Debt / Equity Ratio | 0.16 | 0.20 | 0.23 | 0.24 | 0.31 | 0.41 |
Net Debt / EBITDA Ratio | 2.00 | 2.09 | 2.10 | 9.04 | 2.36 | 10.24 |
Net Debt / FCF Ratio | 6.74 | 8.88 | 20.17 | 7.92 | 4.39 | 3.65 |
Asset Turnover | 1.02 | 1.01 | 0.95 | 0.90 | 0.92 | 0.84 |
Inventory Turnover | 3.46 | 3.40 | 3.39 | 3.14 | 3.27 | 3.42 |
Quick Ratio | 0.72 | 0.63 | 1.13 | 0.53 | 0.54 | 0.58 |
Current Ratio | 1.14 | 1.09 | 2.00 | 0.92 | 1.01 | 0.88 |
Return on Equity (ROE) | 5.18% | 6.09% | 5.97% | -10.58% | 4.97% | -2.24% |
Return on Assets (ROA) | 1.57% | 2.22% | 2.55% | -0.83% | 2.38% | -0.73% |
Return on Invested Capital (ROIC) | 3.35% | 4.81% | 4.90% | -1.97% | 4.06% | -1.67% |
Return on Capital Employed (ROCE) | 3.70% | 5.10% | 4.90% | -1.90% | 5.90% | -2.00% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 7.26% | 6.51% | 5.05% | -7.02% | 3.35% | -1.38% |
FCF Yield | 3.37% | 2.53% | 1.00% | 2.11% | 4.94% | 6.83% |
Payout Ratio | 12.49% | 10.72% | - | - | - | - |
Buyback Yield / Dilution | -2.64% | -0.25% | -0.39% | 0.03% | 0.03% | 0.03% |